As announced by Exor (“Exor” or the “Company”) on 3 August 2022, the Euronext Listing Board has approved the admission to listing and trading of the Company’s ordinary shares (ISIN NL0012059018) on Euronext Amsterdam, a regulated market organized and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations, and as further announced by Exor on 5 August 2022, the Dutch Authority for the Financial Markets (the AFM) has approved the prospectus relating to the admission to listing and trading of the Company’s ordinary shares on Euronext Amsterdam.

As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations, and as announced by Exor on 3 August 2022, the Company has received approval by the Euronext Listing Board of the admission to listing and trading of the Company’s ordinary shares on Euronext Amsterdam.

As announced by Exor (“Exor” or the “Company”) on 29 July 2022, the Company’s board of directors has approved the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, a regulated market organised and managed by Euronext Amsterdam N.V., which hosts some of Europe’s leading corporations.

SHARE BUYBACK TO CONTINUE WITH A SECOND TRANCHE OF UP TO €250 M

Exor (“Exor” or the “Company”) announces that its Board of Directors approved today the transfer of the listing of the Company’s ordinary shares (ISIN NL0012059018) to Euronext Amsterdam, which hosts some of Europe’s leading corporations.

Exor N.V. has closed today the agreement to acquire a 10% shareholding of Institut Mérieux, the privately held global healthcare holding of the Mérieux family. A consideration of €278 million, corresponding to one third of the €833 million total investment, was paid today by way of a reserved capital increase, while the remaining amount is expected to be contributed within the next 12 months.

As part of the partnership sealed with the Mérieux family, John Elkann and Benoît Ribadeau-Dumas have joined Institut Mérieux’s Board of Directors.

Exor announces that it has completed the sale of PartnerRe, the global reinsurer, to Covéa for a total cash consideration of $9.3 billion (approximately €8.6 billion¹). This is based on a consolidated common shareholders’ equity value of $7.3 billion as at 31 December 2021.

The acquisition of PartnerRe by Covéa reinforces PartnerRe’s development as a great company in its industry thanks to a significant increase in the scale and capital strength that membership of a larger financial institution brings, and the value that it represents for its clients.

Exor is investing €833 million to support Institut Mérieux’s growth as it continues to provide key innovative solutions in public health

Institut Mérieux (“Institut Mérieux” or “the Company”), the privately held global healthcare holding of the Mérieux family, and Exor N.V.

Following receipt of the required regulatory approvals, the investment announced on April 22 has been closed: Exor N.V. ("Exor") has today acquired a 45% shareholding in Lifenet S.r.l., an Italian company active in the healthcare sector, particularly in the management of hospitals and outpatient clinics.

The transaction entails a total investment by Exor of €67 million.

Exor N.V. (“Exor” or “the Company”), the diversified holding company controlled by the Agnelli family, announces that meeting today the Company’s Board of Directors resolved to separate the roles of Chairman and Chief Executive Officer.

EXOR N.V. (“Exor” or the “Company”) announces that all the resolutions proposed by the Board of Directors to the Annual General Meeting of Shareholders (the “AGM”) held virtually today were approved.